Combating Antimicrobial Resistance: A Fresh Perspective


ABOUT TXA709


The lead candidate for TAXIS is TXA709, designed for the treatment of methicillin-resistant Staphylococcus aureus (MRSA), a major contributor to the global antibiotic resistance problem. TXA709 inhibits the bacterial protein FtsZ, which plays an essential role in bacterial cell division and survival, distinguishing it from any drug currently in clinical use.

ABOUT FTSZ: A NOVEL TARGET

Bacterial cell division and multiplication occurs through formation of a FtsZ ring, a ring-like structure at the site of cell division. FtsZ is an appealing antibacterial target because it is essential for bacterial survival across many species. Currently available antibiotics do not target cell division processes.

TACKLING THE ANTIBIOTIC RESISTANCE CRISIS:


Overuse and misuse of antibiotic agents have led to the spread of resistant bacteria, posing a serious global health risk that the World Health Organization (WHO) describes as one of the greatest healthcare challenges. TAXIS is focused on developing a new class of antibiotic agents to treat life-threatening, multi-drug resistant bacterial infections.

taxis-home-1

Mission Statement


Our mission is to discover and develop unique therapeutic agents to address the global health crisis of antimicrobial resistance.